



University of  
Nottingham  
UK | CHINA | MALAYSIA

UNIVERSITY OF  
Southampton



# T2T Site Newsletter



## Seasons Greetings from the T2T in Gout Trial Thank you for your continued support

A message from the Chief Investigator,  
Prof. Abhishek.

Thank you very much for supporting the T2T trial and I hope you have a good break during the festive period and the New Year. While recruitment is completed, participants continue to be followed up in the trial. Thank you very much for supporting this important phase of the trial. I look forward to sharing the results with you in 2026.

### Just a reminder....

If there are any new staff members working on the T2T trial, please let us know and we will arrange a training session if required. Please ensure that you also send us an updated copy of the delegation log.



### Recent updates:

- Please ensure that you are using the most current CRFs; CRF05 v2.4 and CRF09 v2.0, please let the study team know if you need any more forms posting out.
- An update to CRF09 has been made to clarify what prevention or treatment is expected in Q1 and Q3.
- There has been an update to the Protocol, now version 8.1, please email the study team to request a copy.

Please continue to book in patients for their follow up appointments. If you are unable to contact a patient to arrange their appointment, then please let us know as we will send them a letter advising them to get in touch. Likewise, if a patient is unable to attend their follow up appointment during the permitted window, please let us know so that we can record this a protocol deviation.

Contact the T2T trial manager | 01782 732950 | : [steff.garvin@nhs.net](mailto:steff.garvin@nhs.net)



# Patient Retention

## Just a reminder about...

... retaining as many patients in the study as we can. We know that the study has a long follow up period and it can be difficult if patients lose interest. Please see below some potential withdrawal reasons based on ones we have already received and some actions to encourage patient to continue to participate. Where possible engage with patients in the intervention arm that are not keen on urate lowering treatment (e.g., allopurinol and febuxostat) to get them back on treatment.

Potential Withdrawal Reason	Actions
<b>Patient has issues with contacting the pharmacy and collecting prescriptions, they feel that their time is being wasted.</b>	Try and address the issue and counsel the patient to stay on treatment. However, if the patient does not want to re-start urate lowering treatment, they can stay in the trial without being on the T2T medication as it is a strategy trial.
<b>Patient does not believe they have gout and believes they have another condition instead.</b>	Ask the patient to speak to their GP – they likely have gout plus another condition.
<b>Patient feels they are not contributing to the study (usual care and not experiencing flares), they no longer wish to participate.</b>	Explain the importance of staying in the trial even if in usual care. Patients in usual care can get urate lowering treatment anytime they wish to do so at their GP surgery. They cannot get treatment from the trained intervention lead.
<b>Patient has had allergic reaction or side-effect to the treatment and wishes to withdraw completely from the study.</b>	Those patients who have had an allergic reaction to allopurinol can try febuxostat. However, if they get allergic reaction to both (rare) or don't want to have febuxostat, patient can stay in the trial without being on the T2T medication as it is a strategy trial.
<b>Patient is not happy to take additional medication, not willing to pay for the medication, and can not take the time off work as it is classed as non-essential.</b>	Patient can stay in the trial without being on the T2T medication as it is a strategy trial.
<b>Patient is unhappy they are in the control arm and no longer wishes to participate.</b>	Explain the importance of staying in the trial even if in usual care.
<b>Patient is unhappy they are in the treatment arm and no longer wishes to participate</b>	Patient can stay in the trial without being on the T2T medication as it is a strategy trial.
<b>Patient no longer wishes to participate; they have been taken off the treatment by their GP to an increase in their INR</b>	Patient can stay in the trial without being on the T2T medication as it is a strategy trial.